I4V-MC-JAJJ: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Delay Stage 3 Type 1 Diabetes in At-risk Participants Aged ≥1 to
Фаза 3 – широко изпитване преди одобрение
Заболявания:
Diabetes Mellitus
Type 1
Спонсор: Eli Lilly & Co.
Налично на:
БГ
Обобщение
Trial status: Authorised
Time from Baseline to Diagnosis of Stage 3 Type 1 Diabetes [Time Frame: Baseline up to approximately 5 years]
Кой може да участва
Age group: 0-17 years, 18-64 years
Gender: Female, Male
Target enrollment: 97 participants
БГ
EN